Phase 1 Metastatic Castration-resistant Prostate Cancer trials recruiting now

All Metastatic Castration-resistant Prostate Cancer trials, every phase

Other phases for Metastatic Castration-resistant Prostate Cancer

Phase 1 Metastatic Castration-resistant Prostate Cancer trials

• 64Cu-GRIP B in Patients With Advanced Malignancies
  NCT05888532 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
  NCT07103018 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 13 locations
• A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
  NCT06879041 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 16 locations
• A Phase I Trial of A-CAR032 in Participants With mCRPC
  NCT07344311 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 5 locations
• A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
  NCT04729114 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 25 locations
• A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
  NCT07719361 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 10 locations
• A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
  NCT07189403 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 6 locations
• A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
  NCT06531499 · Phase: Phase 1 · Ages: 18 Years to 100 Years · Sex: Male · 21 locations
• A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
  NCT04104776 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 160 locations
• A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
  NCT07244341 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 19 locations
• A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
  NCT06067841 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 15 locations
• A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients
  NCT06155084 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 27 locations
• A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer
  NCT07339267 · Phase: Phase 1 · Ages: 18 Years to 85 Years · Sex: Male · 1 location
• A Trial of HRS-5041-103 to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-5041 in Subjects With Metastatic Castration-resistant Prostate Cancer
  NCT06830850 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 11 locations
• A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer
  NCT05125016 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 14 locations
• ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium
  NCT07414940 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
  NCT05113537 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
  NCT05413850 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 21 locations
• Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
  NCT06193486 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
  NCT05613894 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
  NCT07641049 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 1 location
• EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&T
  NCT05521412 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer
  NCT06480110 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 1 location
• FOG-001 in Locally Advanced or Metastatic Solid Tumors
  NCT05919264 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 33 locations
• Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
  NCT05720130 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Male · 3 locations
• Study With [225Ac]Ac-FL-020 in mCRPC Participants
  NCT06492122 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 11 locations
• Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
  NCT07288359 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 30 locations
• Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
  NCT05519449 · Phase: Phase 1 · Ages: 18 Years to 100 Years · Sex: Male · 36 locations
• Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer
  NCT07545811 · Phase: Phase 1 · Ages: 18 Years and older · Sex: Male · 6 locations

Common questions

What does Phase 1 mean?

See how clinical trials work.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.